Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Chromatin Accessibility Identifies Regulatory Elements Predictive of Oncogene Expression in Multiple Myeloma

Benjamin G Barwick, PhD, Vikas A. Gupta, MD PhD, Shannon M Matulis, PhD, Jonathan C Patton, B.S., Doris R Powell, MA, Yanyan Gu, MD PhD, David L. Jaye, MD, Karen N Conneely, PhD, Yin C Lin, PhD, Craig C Hofmeister, MDMPH, Ajay Nooka, MDMPH, Jonathan J Keats, PhD, Sagar Lonial, MD FACP, Paula M Vertino, PhD, Larry H. Boise, PhD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-140717

Published: 2020

Journal Articles

Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-142110

Published: 2020

Journal Articles

Statins Enhance Killing of Multiple Myeloma Cells By the BCL-2 Inhibitor Venetoclax and the MCL-1 Inhibitor S63845

David Fruman, PhD, Dennis Juarez, B.S., Grace Diep, Undergraduate, Falisha Nguyen, Undergraduate, Vikas A. Gupta, MD PhD, Lawrence H. Boise, PhD

Blood (2019) 134 (Supplement_1): 4413.

https://doi.org/10.1182/blood-2019-131218

Published: 2019

Journal Articles

The Role of Proteasome Activator PA28α in Multiple Myeloma

Yanyan Gu, MD PhD, Benjamin G Barwick, PhD, Mala Shanmugam, PhD, Craig C Hofmeister, MDMPH, Jonathan L. Kaufman, MD, Ajay K Nooka, MDMPH, Vikas A. Gupta, MD PhD, Madhav V Dhodapkar, MBBS, Lawrence H. Boise, PhD, Sagar Lonial

Blood (2019) 134 (Supplement_1): 5499.

https://doi.org/10.1182/blood-2019-128216

Published: 2019

Journal Articles

Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy

Benjamin G Barwick, PhD, Paola Neri, MD, Nizar Bahlis, MD, Ajay K Nooka, MDMPH, Jonathan L Kaufman, MD, Vikas A. Gupta, MD PhD, Daniel Auclair, PhD, Jonathan J Keats, PhD, Sagar Lonial, MD, Paula M Vertino, PhD, Lawrence H. Boise, PhD

Blood (2018) 132 (Supplement 1): 405.

https://doi.org/10.1182/blood-2018-99-113585

Published: 2018

Journal Articles

Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone

Timothy M. Schmidt, MD, Nisha Joseph, MD, Levani Odikadze, MD MPH, Leonard Heffner, MD, Craig C Hofmeister, MD MPH, Madhav V Dhodapkar, MD, Vikas A. Gupta, MD PhD, Lawrence H. Boise, PhD, David L. Jaye, MD, Sagar Lonial, MD, Ajay K Nooka, MD MPH, Jonathan L Kaufman, MD

Blood (2018) 132 (Supplement 1): 3241.

https://doi.org/10.1182/blood-2018-99-112216

Published: 2018

Journal Articles

Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients

Nisha Joseph, MD, Vikas A. Gupta, MD PhD, Craig C Hofmeister, MD MPH, Charise Gleason, ANP, Leonard Heffner, MD, Lawrence H. Boise, PhD, Jonathan L Kaufman, MD, Madhav V Dhodapkar, MD, Sagar Lonial, MD, Ajay K Nooka, MD MPH

Blood (2018) 132 (Supplement 1): 3294.

https://doi.org/10.1182/blood-2018-99-119895

Published: 2018

Journal Articles

Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma

Shannon M Matulis, PhD, Vikas A. Gupta, MD PhD, Izabelle Brown, Jonathan J Keats, PhD, Paul Secrist, PhD, Justin Cidado, PhD, Adriana E. Tron, PhD, Paola Neri, MD, Nizar Bahlis, MD, Jonathan L Kaufman, MD, Leonard Heffner, MD, Sagar Lonial, MD, Ajay K Nooka, MDMPH, Lawrence H. Boise, PhD

Blood (2018) 132 (Supplement 1): 952.

https://doi.org/10.1182/blood-2018-99-113504

Published: 2018

Journal Articles

Differences in Presentation and Survival Outcomes for African American Patients with Newly Diagnosed Multiple Myeloma

Blood (2018) 132 (Supplement 1): 5647.

https://doi.org/10.1182/blood-2018-99-119948

Published: 2018

Journal Articles

The Impact of a Physical Activity Intervention Can be Accurately Assessed By Smart Watches in Patients Completing Autologous Stem Cell Transplantation for Lymphoma or Multiple Myeloma: Results of a Feasibility Study

Blood (2018) 132 (Supplement 1): 5911.

https://doi.org/10.1182/blood-2018-99-119757

Published: 2018

Journal Articles

Outcomes of Myeloma Patients with t(11;14) Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy

Jonathan L Kaufman, MD, Nisha Joseph, MD, Vikas A. Gupta, MD PhD, Charise Gleason, ANP, Craig C Hofmeister, MD MPH, Leonard Heffner, MD, Madhav V Dhodapkar, MD, Sagar Lonial, MD, Lawrence H. Boise, PhD, Ajay K Nooka, MD MPH

Blood (2018) 132 (Supplement 1): 3282.

https://doi.org/10.1182/blood-2018-99-119051

Published: 2018

Journal Articles

Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy

Levani Odikadze, MD MPH, Nisha Joseph, MD, Timothy M. Schmidt, MD, Leonard Heffner, MD, Craig C Hofmeister, MD MPH, Madhav V Dhodapkar, MD, Vikas A. Gupta, MD PhD, Lawrence H. Boise, PhD, David L. Jaye, MD, Sagar Lonial, MD, Ajay K Nooka, MD MPH, Jonathan L Kaufman, MD

Blood (2018) 132 (Supplement 1): 1884.

https://doi.org/10.1182/blood-2018-99-114368

Published: 2018

Journal Articles

Succinate Ubiquinone Reductase Activity Predicts Multiple Myeloma Sensitivity to Venetoclax

Richa Bajpai, PhD, Changyong Wei, PhD BS, Shannon Matulis, PhD, Ajay K. Nooka, MDMPH, Samuel McBrayer, PhD, Sagar Lonial, MD, Vikas A. Gupta, MD PhD, Lawrence H. Boise, PhD, Mala Shanmugam, PhD

Blood (2017) 130 (Supplement 1): 4409.

https://doi.org/10.1182/blood.V130.Suppl_1.4409.4409

Published: 2017

Journal Articles

A B-Cell like Phenotype Is Associated with Sensitivity to Venetoclax in Multiple Myeloma

Vikas A. Gupta, MD PhD, Benjamin Barwick, PhD, Scott Newman, PhD, Jonathan J. Keats, PhD, Daniel Auclair, PhD, Shannon Matulis, PhD, Michael R. Rossi, PhD, Ajay K. Nooka, MDMPH, Jonathan L. Kaufman, MD, Sagar Lonial, MD, Lawrence H. Boise, PhD

Blood (2017) 130 (Supplement 1): 3073.

https://doi.org/10.1182/blood.V130.Suppl_1.3073.3073

Published: 2017

Journal Articles

Predicting Venetoclax Sensitivity in Multiple Myeloma Using Biologic Activity Assays

Shannon Matulis, PhD, Vikas A. Gupta, MD PhD, Zenchu Tang, Shardule Shah, Tolu Adewuya, Ajay Nooka, MDMPH, Jonathan L. Kaufman, MD, Sagar Lonial, MD, Lawrence H. Boise, PhD

Blood (2017) 130 (Supplement 1): 3056.

https://doi.org/10.1182/blood.V130.Suppl_1.3056.3056

Published: 2017

Journal Articles

High-Risk Myeloma Is Demarcated By Immunoglobulin Lambda Light Chain Translocations

Benjamin Barwick, PhD, Vikas A. Gupta, MD PhD, Daniel Auclair, PhD, Jonathan J. Keats, PhD, Sagar Lonial, MD, Paula M Vertino, PhD, Lawrence H. Boise, PhD

Blood (2017) 130 (Supplement 1): 1780.

https://doi.org/10.1182/blood.V130.Suppl_1.1780.1780

Published: 2017

Journal Articles

Assessing Individual Comorbidities in Elderly Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplant — Obesity Associated with Inferior Outcomes

Andrew Ip, MD, Jeffrey M. Switchenko, PhD MS, Michael Graiser, Jean L. Koff, MD, Vikas A. Gupta, MD PhD, Ajay K. Nooka, MDMPH, Zaid Al-Kadhimi, MD, Mary Jo Lechowicz, MD, Jonathan L. Kaufman, MD, Sagar Lonial, MD, Edmund K. Waller, MD, Amelia Langston, MD, Christopher Flowers, MD, Jonathon B Cohen, MDMS

Blood (2017) 130 (Supplement 1): 5516.

https://doi.org/10.1182/blood.V130.Suppl_1.5516.5516

Published: 2017

Journal Articles

B-Cell Markers Predict Response to Venetoclax in Multiple Myeloma

Vikas A. Gupta, MD PhD, Scott Newman, PhD, Nizar J. Bahlis, MD, Jonathan J Keats, PhD, Shannon Matulis, PhD, Michael R. Rossi, PhD, Daniel Auclair, PhD, Mmrf CoMMpass Network, Ajay K Nooka, MD MPH, Jonathan L. Kaufman, MD, Sagar Lonial, MD FACP, Lawrence H. Boise, PhD

Blood (2016) 128 (22): 2108.

https://doi.org/10.1182/blood.V128.22.2108.2108

Published: 2016

Journal Articles

Efficacy and Safety of Triplet Versus Doublet Salvage Therapies Among Patients with Multiple Myeloma (MM) Experiencing Early Relapse: Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)

Ajay K. Nooka, MD MPH, Jonathan L. Kaufman, MD, Madhusmita Behera, PhD, Charise Gleason, MSN, ANP-BC, AOCNP, Hannah Collins, ANP-BC, OCN, Vikas A. Gupta, MD PhD, Lawrence H Boise, PhD, Sagar Lonial, MD

Blood (2015) 126 (23): 5344.

https://doi.org/10.1182/blood.V126.23.5344.5344

Published: 2015

Journal Articles

Phosphorylation Influences The Binding Of Bim To Anti-Apoptotic Proteins In Multiple Myeloma

Jason E. Conage-Pough, Vikas A. Gupta, MD, PhD, Shannon M. Matulis, Ph.D., Lawrence H. Boise, PhD

Blood (2013) 122 (21): 4446.

https://doi.org/10.1182/blood.V122.21.4446.4446

Published: 2013

NARROW

Chromatin Accessibility Identifies Regulatory Elements Predictive of Oncogene Expression in Multiple Myeloma

Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era

Statins Enhance Killing of Multiple Myeloma Cells By the BCL-2 Inhibitor Venetoclax and the MCL-1 Inhibitor S63845

The Role of Proteasome Activator PA28α in Multiple Myeloma

Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy

Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone

Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients

Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma

Differences in Presentation and Survival Outcomes for African American Patients with Newly Diagnosed Multiple Myeloma

The Impact of a Physical Activity Intervention Can be Accurately Assessed By Smart Watches in Patients Completing Autologous Stem Cell Transplantation for Lymphoma or Multiple Myeloma: Results of a Feasibility Study

Outcomes of Myeloma Patients with t(11;14) Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy

Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy

Succinate Ubiquinone Reductase Activity Predicts Multiple Myeloma Sensitivity to Venetoclax

A B-Cell like Phenotype Is Associated with Sensitivity to Venetoclax in Multiple Myeloma

Predicting Venetoclax Sensitivity in Multiple Myeloma Using Biologic Activity Assays

High-Risk Myeloma Is Demarcated By Immunoglobulin Lambda Light Chain Translocations

Assessing Individual Comorbidities in Elderly Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplant — Obesity Associated with Inferior Outcomes

B-Cell Markers Predict Response to Venetoclax in Multiple Myeloma

Efficacy and Safety of Triplet Versus Doublet Salvage Therapies Among Patients with Multiple Myeloma (MM) Experiencing Early Relapse: Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)

Phosphorylation Influences The Binding Of Bim To Anti-Apoptotic Proteins In Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only